Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. More Details
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has Sino Biopharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1177 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1177's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1177 underperformed the Hong Kong Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: 1177 underperformed the Hong Kong Market which returned 10.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Sino Biopharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
16 hours ago | Simply Wall StSino Biopharmaceutical Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
1 week ago | Simply Wall StSino Biopharmaceutical Limited's (HKG:1177) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
3 weeks ago | Simply Wall StEstimating The Fair Value Of Sino Biopharmaceutical Limited (HKG:1177)
Is Sino Biopharmaceutical undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1177 (HK$6.65) is trading above our estimate of fair value (HK$5.68)
Significantly Below Fair Value: 1177 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1177 is poor value based on its PE Ratio (46.1x) compared to the HK Pharmaceuticals industry average (11x).
PE vs Market: 1177 is poor value based on its PE Ratio (46.1x) compared to the Hong Kong market (11.1x).
Price to Earnings Growth Ratio
PEG Ratio: 1177 is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: 1177 is overvalued based on its PB Ratio (3.4x) compared to the HK Pharmaceuticals industry average (1.1x).
How is Sino Biopharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1177's forecast earnings growth (26.1% per year) is above the savings rate (1.6%).
Earnings vs Market: 1177's earnings (26.1% per year) are forecast to grow faster than the Hong Kong market (22.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1177's revenue (16.4% per year) is forecast to grow faster than the Hong Kong market (13.8% per year).
High Growth Revenue: 1177's revenue (16.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1177's Return on Equity is forecast to be low in 3 years time (10.3%).
How has Sino Biopharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1177 has high quality earnings.
Growing Profit Margin: 1177's current net profit margins (10%) are lower than last year (36.9%).
Past Earnings Growth Analysis
Earnings Trend: 1177's earnings have grown significantly by 25.8% per year over the past 5 years.
Accelerating Growth: 1177's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1177 had negative earnings growth (-74.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-12.9%).
Return on Equity
High ROE: 1177's Return on Equity (9.9%) is considered low.
How is Sino Biopharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 1177's short term assets (CN¥30.4B) exceed its short term liabilities (CN¥9.9B).
Long Term Liabilities: 1177's short term assets (CN¥30.4B) exceed its long term liabilities (CN¥15.8B).
Debt to Equity History and Analysis
Debt Level: 1177's debt to equity ratio (35.1%) is considered satisfactory.
Reducing Debt: 1177's debt to equity ratio has increased from 17.4% to 35.1% over the past 5 years.
Debt Coverage: 1177's debt is well covered by operating cash flow (23.7%).
Interest Coverage: 1177 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Sino Biopharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 1177's dividend (0.8%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.18%).
High Dividend: 1177's dividend (0.8%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.58%).
Stability and Growth of Payments
Stable Dividend: 1177 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 1177 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 1177 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1177's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yi Li (58 yo)
Mr. Yi Li serves as Chief Executive Officer and Executive Director at Sino Biopharmaceutical Limited since August 19, 2020. He joined J.P. Morgan China in October 2014 as chairman and chief executive offic...
|Founder & Senior Vice Chairman||0.33yr||CN¥44.61m||7.92% |
|Executive Vice Chairwoman of the Board||3.67yrs||CN¥27.96m||4.68% |
|VP & Executive Director||5.67yrs||CN¥985.00k||no data|
|Executive Director||5.67yrs||CN¥2.43m||no data|
|VP & Executive Director||no data||CN¥3.17m||0.88% |
|Executive Director||1.17yrs||CN¥6.16m||21.55% |
|Executive Chairman of the Board||5.5yrs||no data||no data|
|CEO & Executive Director||0.33yr||no data||0.0012% |
|Independent Non-Executive Director||15.08yrs||CN¥349.00k||no data|
|Independent Non-Executive Director||16.25yrs||CN¥349.00k||no data|
|Executive Director||5.67yrs||CN¥5.58m||no data|
|Independent Non-Executive Director||5.67yrs||CN¥349.00k||no data|
Experienced Board: 1177's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 1177 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sino Biopharmaceutical Limited's company bio, employee growth, exchange listings and data sources
- Name: Sino Biopharmaceutical Limited
- Ticker: 1177
- Exchange: SEHK
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$129.275b
- Shares outstanding: 18.79b
- Website: https://www.sinobiopharm.com
Number of Employees
- Sino Biopharmaceutical Limited
- Office Tower
- Unit 09, 41st Floor, Room 4109
- Wan Chai
- Hong Kong
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1177||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Sep 2000|
|SMZ1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Sep 2000|
|SBMF.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Sep 2000|
|1177||SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Sep 2000|
|1177||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Sep 2000|
|SBHM.Y||OTCPK (Pink Sheets LLC)||ADR||US||USD||Jul 2014|
Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. The company operates in three segments:...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 10:10|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.